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MicroRNAs (miRNAs) belong to an abundant class of highly con-
served small (22nt) non-coding RNAs. 
MiRNA profiling studies indicate that 
their expression is highly cell type-depen-
dent. DICER1 is an essential RNase III 
endoribonuclease for miRNA process-
ing. Hematopoietic cell type- and devel-
opmental stage-specific Dicer1 deletion 
models show that miRNAs are essential 
regulators of cellular survival, differ-
entiation and function. For instance, 
miRNA deficiency in hematopoietic stem 
cells and progenitors of different origins 
results in decreased cell survival, dra-
matic developmental aberrations or dys-
functions in mice. We recently found that 
homozygous Dicer1 deletion in myeloid-
committed progenitors results in an aber-
rant expression of stem cell genes and 
induces a regained self-renewal capac-
ity. Moreover, Dicer1 deletion causes a 
block in macrophage development and 
myeloid dysplasia, a cellular condition 
that may be considered as a preleukemic 
state. However, Dicer1-null cells do not 
develop leukemia in mice, indicating that 
depletion of miRNAs is not enough for 
tumorigenesis. Surprisingly, we found 
that heterozygous Dicer1 deletion in 
myeloid-committed progenitors, but not 
Dicer1 knockout, collaborates with p53 
deletion in leukemic progression and 
results in various types of leukemia. Our 
data indicate that Dicer1 is a haploinsuf-
ficient tumorsuppressor in hematopoietic 
neoplasms, which is consistent with the 
observed downregulation of miRNA 
expression in human leukemia samples. 
Here, we review the various hematopoi-
etic specific Dicer1 deletion mouse models 
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and the phenotypes observed within the 
different hematopoietic lineages and cell 
developmental stages. Finally, we dis-
cuss the role for DICER1 in mouse and 
human malignant hematopoiesis.
Introduction
DICER1 is an evolutionarily conserved 
member of the RNase III family of endori-
bonucleases. The gene encoding DICER1 
is located on human chromosome 14q32 
and mouse chromosome 12E. DICER1 
is a complex protein and contains three 
N-terminal Helicase domains (HEL1, 
HEL2i, HEL2), a DUF283 domain, 
which is presumably involved in bind-
ing of double-stranded RNA (dsRNA), a 
Platform domain, the pre-miRNA bind-
ing domain PAZ, RNase IIIa, RNase IIIb 
and a C-terminal dsRNA binding domain 
(dsRBD).1-3 The RNase III domains of 
DICER1 cleave double-stranded RNA 
(dsRNA) substrates and specific precursor 
hairpin sequences, including so-called pre-
miRNAs, into small 5'-phosphorylated 
RNAs of typically 21–23 nucleotides called 
miRNA.4 Deep sequencing of 5'-phos-
phorylated short RNAs in ES cells showed 
that the miRNA is the only class of short 
RNAs to be fully DICER1-dependent.5 
However, the premature miR-451 is the 
single well-conserved miRNA-containing 
sequence known to bypass DICER1 pro-
cessing and is matured by an Argonaute-2 
(Ago-2)-dependent mechanism.6-9 The 
DICER1-generated short RNAs bind to 
Argonaute proteins in the so-called RNA-
induced silencing complex (RISC). This 
complex induces degradation or inhibits 
translation of homologs target mRNAs. 
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Tregs, using a Foxp3-Cre knock-in mouse 
(Fig. 1C).21,22 Under steady-state condi-
tions, Foxp3-controlled deletion of Dicer1 
has minimal effects on Treg cell develop-
ment, cellular proliferation and survival in 
the peripheral compartments.22 However, 
a diminished fitness of Dicer1-deficient 
Treg cells in the periphery was observed in 
a competitive experiment in mice.21 Under 
inflammatory conditions, the immune-
repressive capacity of the mutant Treg 
cells is markedly reduced and results in 
rapid fatal autoimmunity and complete 
failure of immune suppression activity.21,22 
Moreover, Dicer1 deletion in Treg cells 
leads to the progression of fatal lympho-
proliferative autoimmune syndrome with 
an early onset, which is indistinguish-
ably comparable to T-cell-specific Foxp3 
deficiency.21 The expression of putative 
suppressor effector molecules, includ-
ing CTLA4, IL-10, EBV-induced gene 3 
(Ebi-3) and granzyme B, was decreased 
by still-unidentified miRNA-controlled 
mechanisms.21 Tregs express a specific set 
of miRNAs, including miR-223, miR-155 
and miR-146, which is distinct from naïve 
CD4+ T-cells.20 Therefore, the expression 
of these miRNAs may be under direct or 
indirect control of the transcription fac-
tor Foxp3.20 Identification of the targets 
that are controlled by these miRNAs in 
Tregs may provide new insights about the 
molecular pathways involved in the activ-
ity of these cells.
The role of miRNAs in invariant 
Natural Killer T (iNKT) cells was studied 
in a mouse strain by Tie2-Cre-mediated 
disruption of Dicer1.23 The Tie2 kinase 
is specifically expressed in hematopoi-
etic progenitors and endothelial cells.24 
Similar to the immune phenotypes in 
CD4-Cre;Dicer1fl/fl and Lck-Cre;Dicer1fl/ fl, 
these mice show reduced numbers of 
iNKT cells in the thymus, spleen and liver. 
Moreover, Dicer1 deletion results in devel-
opmental abnormalities of iNKT cells.23,25 
In addition, Dicer1-deficient peripheral 
iNKT cell numbers are decreased and 
displayed profound defects in α-GalCer, 
phorbol myristate acetate (PMA) and 
ionomycin-induced cellular activation 
and production of cytokines such as IL-4 
and IFN-γ.23 Together, these data indicate 
that Dicer1 controls survival at the early 
T-cell developmental stage. At the later 
to be essential for the generation and sur-
vival of αβ T-cells. However, in the sur-
viving T-cells, Dicer1 is dispensable for 
CD4+ and CD8+ single positive lineage 
commitment.18 These results strongly sug-
gest that Dicer1 deletion does not affect 
normal T-cell lineage-specific gene expres-
sion programs. In these cells, the transcrip-
tional repression of centromeric satellite 
repeats and features of facultative hetero-
chromatin are maintained in the absence 
of Dicer1,18 suggesting that survival of 
immature T-cells is regulated directly by a 
miRNA-controlled mechanism.
The CD4-Cre transgenic mouse model 
enables investigation of the consequences 
of Dicer1 deletion at a later stage of T 
cell development (Fig. 1B). These mice 
show four major phenotypes: (1) Dicer1 
is required for basic cellular processes, 
such as proliferation and survival, as also 
proposed by Cobb et al., and therefore 
Dicer1 deficiency results in decreased 
number of T-cells.18,19 (2) Dicer1 deletion 
appears to favor T-cell lineage production 
from CD4+CD8+ double-positive stage 
toward CD4+ single-positive peripheral 
T-cells over CD8+ single-positive cells. 
However, this phenotype was less obvious 
from thymic T-cell lineage analysis. This 
discrepancy may be explained by the fact 
that CD4-Cre-driven deletion of Dicer1 
does not result in complete depletion 
of all miRNAs, presumably due to high 
miRNA stability and limited cell divisions 
of a small fraction of CD4+ T-cells, which 
may be different for Dicer1-null CD8+ 
T-cells. (3) Dicer1-null CD4+ T-cells pro-
duce increased levels of IFN-γ, a pro-Th1 
cytokine, indicating that Dicer1 controls 
Th1-lineage commitment.19 (4) CD4-Cre; 
Dicer1fl/fl mice show a more than 2-fold 
decreased proportion of Foxp3+ regula-
tory T cells (Treg).20 Interestingly, these 
mice developed a splenomegaly, and their 
lymph nodes were severely enlarged at the 
age of 3 to 4 mo. Moreover, organs such 
as colon, lung and liver were affected by 
immune pathology caused by an overac-
tive immune system, which is less severe 
as compared with Foxp3-knockout mice 
lacking functional Tregs.20 However, this 
phenotype suggests that Dicer1-deficient 
Tregs are functionally aberrant as well.
Two studies revealed the role of Dicer1 
more specifically in the function of mature 
Moreover RISC triggers gene silencing via 
chromatin modifications at target promot-
ers under specific conditions such as cel-
lular senescence.10,11
Genetic studies in plants, zebrafish and 
mice show that Dicer1 is essential for nor-
mal development.12-14 For instance, genetic 
deletion of Dicer1 in mice results in early 
embryonic mortality due to depletion of 
the Oct-4-positive pluripotent embry-
onic stem cell pool at embryonic day (E) 
6-E7.14 Dicer1-null ES cells are incapable 
of processing miRNA hairpins or dsR-
NAs.5,15,16 However, Dicer1 is dispensable 
for the siRNA-mediated gene silencing 
response.16 Although a role for Dicer1 in 
centromeric silencing has been suggested, 
deep sequencing of small RNAs in Dicer1-
null and Dicer1 wild type ES cells indi-
cates that the production of miRNAs is 
the sole catalytic function of DICER1 in 
these cells.5 To bypass embryonic lethal-
ity and to enable investigation of Dicer1 
functions in adult tissues in mice, a floxed 
Dicer1 allele (Dicer1fl) has been generated 
that allows conditional deletion of Dicer1 
in a cell type- and developmental stage-
specific fashion.17 To address the overall 
role of miRNAs in the development and 
function of hematopoietic cells, differ-
ent hematopoietic cell stage and lineage-
specific conditional Dicer1 deletion strains 
have been used. First, we will review the 
phenotypic consequences of Dicer1 dele-
tion at different stages of hematopoiesis 
and cell types. Second, we discuss what 
we have learned from these models about 
miRNA-controlled pathways in hema-
topoiesis. Finally, we show evidence for 
Dicer1 haploinsufficient tumorsuppressor 
activity in mouse leukemia and discuss the 
role for DICER1 in human AML.
The Role of Dicer1 in  
T-Lymphocyte Development
In one of the first studies addressing the 
role of Dicer1 in hematopoiesis in vivo, 
floxed Dicer1 alleles were deleted by CRE 
in lymphocyte-specific protein tyrosine 
kinase (Lck)-positive cells. In this model, 
Cre is active at the double-negative (DN) 
CD4-CD8- T cell developmental stage 
and results in Dicer1-null CD44-CD25- 
(DN4), CD4+CD8+ and CD4+CD8-, 
CD4-CD8- cells (Fig. 1A).18 Dicer1 seems 
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inhibitory genes, such as Cdkn1c (p57Kip2), 
Cdkn2b (p16INK4a), Cdk1a (p21Cip1) and 
Cdkn1b (p27Kip).29 Furthermore, Dicer1 
deletion in B-cells leads to massive induc-
tion of apoptosis due to derepression of the 
proapoptotic protein BIM1 as described 
for early stages of B-cell development.29 
Together, these data show that Dicer1 con-
trols survival of B-cells at different stages 
of B-cell development, regulates cellu-
lar proliferation and is critical for proper 
B- and plasma cell functions.
The Role for Dicer1  
in NK Cell Function
Bezman et al. induced ablation of con-
ditional Dicer1 alleles with a tamoxi-
fen-inducible Cre recombinase (human 
estrogen receptor (ERT2)-Cre) and studied 
the effects of miRNA depletion in NK 
cells.30 This non-specific model revealed 
a role for Dicer1 in the maintenance of 
produce high titers of autoreactive anti-
bodies and as a result cause autoimmune 
disease in aged female mice.28 However, 
the miRNAs that control autoreactivity 
are still unidentified.
To investigate the role for Dicer1 in 
antigen-activated, but not naive B cells, 
an activation-induced cytadine deami-
nase (Aicda)-Cre-mediated Dicer1 dele-
tion mouse model has been generated.29 
This mouse model showed that Dicer1 is 
required for the production of antigen-
specific high-affinity antibodies during 
a T-cell-dependent immune response.29 
Also, the formation of germinal center 
B cells is drastically impaired in Dicer1-
deficient mice.29 These mutant mice fail 
to generate memory B and long-lived 
plasma cells after immunization with a 
T cell-dependent antigen. This study pro-
vides evidence for Dicer1-controlled cell 
proliferation of activated germinal center 
B-cells by strong repression of cell cycle 
stage, Dicer1 is critical for the balance of 
Th1/Th2 lineage production and controls 
functions such as immune-repression and 
specific cellular activity.
Dicer1 Function During B Cell 
Development
Ablation of Dicer1 in early B cell pro-
genitors, mediated by the Mb1-Cre allele, 
which is expressed at the earliest stage 
of B-cell development, blocks B-cell 
development almost completely at the 
pro-B-cell (B220low, c-kit+ CD25-) to pre-
B-cell (B220int, c-kit-, CD25+) transition 
(Fig. 1D).26 This block in B-cell develop-
ment is caused by a strong induction of 
apoptosis and results in total depletion of 
B cells in the BM and the peripheral lym-
phoid organs in mice.26 Gene expression 
profiling of Abelson virus (v-Abl)-trans-
formed Dicer1-null pro-B-cells revealed 
that miR-142–3p and different members 
of the miR-17~92 family of miRNA, such 
as miR-17, miR-19, miR-20 and miR-92, 
are the most active at the pro-B-cell 
stage.26 Derepression of the proapop-
totic protein BIM, a confirmed target 
of miR-17~92, was shown to be mainly 
responsible for the failure of the cells to 
respond to survival signals.26 In full agree-
ment, Ventura A and colleagues have dem-
onstrated that deletion of the miR-17~92 
in mouse hematopoietic stem cells leads to 
a cell development arrest at the pro-B to 
pre-B transition that is highly reminiscent 
of what has been observed in the Dicer1-
deficient mice.27
The role of miRNAs in terminal B cell 
differentiation is addressed by the analy-
sis of CD19-Cre driven Dicer1-deletion 
mouse model (Fig. 1E).28 In contrast 
to early MB1-Cre driven Dicer1 dele-
tion, depletion of Dicer1 with CD19-Cre 
in immature B220+ IgM+ cells does not 
induce cell death and allowed analysis 
of the role for Dicer1 in mature B cells 
in peripheral tissues.28 In the absence of 
Dicer1, transitional and marginal zone 
B cells are overrepresented, and the genera-
tion of follicular B cells is impaired.28 The 
miR-185 is abundantly expressed in fol-
licular B-cells and controls the expression 
of B cell antigen receptor (BCR) signaling 
effector Bruton tyrosine kinase (BtK) in 
activated B cells.28 Dicer1-deficient B cells 
Figure 1. Schematic overview of the phenotypic characteristics of different Cre-mediated Dicer1-
deletion models in lymphopoiesis (A) HSCs develop via different progenitors toward mature CD4+ 
or CD8+ single positive cells. the effects of LCK-Cre-mediated Dicer1 deletion are depicted. the 
apparent level of Dicer1 expression is indicated by the yellow background color (yellow, normal 
endogenous levels; white, no Dicer1 expression). HSC, hematopoietic stem cells; CLP, common 
lymphoid progenitor; DN1–3, double-negative stage 1 to 3 (CD4-CD8-); DN4, double-negative 
stage 4, DP: double-positive CD4+CD8+ cells. Phenotypic characteristics are indicated by the red 
arrows nd lines. Dashed lines indicate less cells than in wild-type situation (B). See also (A). the ef-
fects of CD4-Cre-mediated Dicer1 deletion are depicted. Phenotypic characteristics are indicated 
by the red arrow and lines (C). See also (A). the effects of FoxP3-Cre-mediated Dicer1 deletion 
results in normal numbers of regulatoty t-cells (tregs), but these cells are functionally aberrant. 
(D) HSCs develop via indicated progenitors toward mature B-cells. the effects of MB1-Cre-medi-
ated Dicer1 deletion are indicated by the red lines and arrow and result in developmental block 
from the pro-B-cell to the pre-B-cell stage. Pro-B: earliest stage of progenitor B-cell development, 
pre-B-cell, precursor stage of B-cell development (e). See also (D). CD19-Cre-mediated deletion of 
Dicer1 results in mature B-cells which are functionally aberrant.
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(HSPCs) was first studied by breeding 
Dicer1fl/fl with Mx-Cre mice.32 These mice 
express the Cre-recombinase in response 
to interferons and are highly efficient in 
recombination of floxed alleles in the 
hematopoietic system in vivo via perito-
neal injection of polyI:polyC (pIpC).32 
Dicer1 ablation in these mice depletes 
functional HSCs, induces rapid apoptosis 
in HSPCs and consequently causes total 
disruption of hematopoiesis.32 In addi-
tion, miRNA-depleted HSCs are unable 
to reconstitute hematopoiesis in mice.32 In 
full agreement, Dicer1fl/fl HSCs contain-
ing the VAVi-Cre transgene that is highly 
active in HSCs and efficient in deletion 
of floxed alleleles33 are incapable to recon-
stitute lethally irradiated recipient mice 
(Erkeland SJ et al., unpublished data). 
Together, these data show that Dicer1 is 
essential for HSCs survival. Interestingly, 
miR-125a controls the expansion of HSCs 
in vivo through targeting the proapototic 
gene Bak1. Whether miR-125a as a single 
miRNA can rescue Dicer1-null HSC sur-
vival and functions remains elusive, but it 
is more likely that multiple miRNAs are 
critical at this stage.
To address the question whether miR-
NAs play a role in early myeloid-lineage 
decisions, we deleted Dicer1 in CCAAT/
enhancer-binding protein α (C/EBPA)-
positive myeloid-committed progenitors 
in vivo (Fig. 2).34 In striking contrast 
to the results in HSCs and early lym-
phoid progenitors, we recently found 
that miRNA depletion does not affect 
the number of myeloid-committed pro-
genitor cells in mice.34 However, isolated 
Dicer1-deficient granulocyte-macrophage 
progenitors (GMPs) were defective in 
myeloid development and exhibited an 
increased self-renewal potential.34 In mice, 
Dicer1 deletion by C/ebpa-Cre blocked 
monocytic differentiation, depleted mac-
rophages and myelo-dendritic cells and 
caused myeloid dysplasia with morpho-
logical features of Pelger-Huet anomaly34 
(Fig. 2). Strikingly, monocytes express low 
levels of proteins involved in miRNA pro-
cessing and functions such as DROSHA, 
AGO1 and AGO2 compared with the 
levels found in T-cells, and are deficient 
for DICER1, unless the cells are forced 
to differentiate toward macrophages.35,36 
The presence of some miRNAs in the 
as IL-15 and IL-12, tumor target cells, 
activating NK cell receptor ligation as 
well as during acute MCMV infection in 
vivo.31 The miR-15/16 family of miRNAs 
is potentially contributing to IFN-γ sup-
pression and may control dampening of 
NK cell functions.31
Dicer1 Deletion in Myeloid- 
Committed Progenitors Revealed 
an Unexpected Function  
in Hematopoiesis
The consequences of Dicer1 deletion in 
hematopoietic stem and progenitor cells 
survival and function of NK cells.30 They 
found that in response to a viral infection 
with mouse cytomegalovirus (MCMV), 
the expansion of NK cells, but not the 
IFN-γ production, is Dicer1-dependent, 
suggesting that survival but not activity of 
NK cells is affected by Dicer1 deficiency.30 
Similarly, HCD2-Cre;Dicer1fl/fl mice, 
which enable a lymphocyte-restricted 
Dicer1 deletion at the early stage of NK 
cells development, also showed reduced 
NK cell maturation and survival.30,31 
However, Dicer1-null NK cells showed 
enhanced degranulation and IFN-γ pro-
duction in response to cytokines such 
Figure 2. Schematic overview of the results of C/ebpa-Cre-mediated deletion of Dicer1 in 
myeloid-committed progenitors. Phenotypic characteristics are indicated in red. in short, dele-
tion of Dicer1 results in derepression of stem cell genes in myeloid progenitors and an enhanced 
self-renewal capacity. Furthermore, MDPs and GMPs are blocked in macrophage and dendritic cell 
development. in addition, Dicer1 deletion results in neutrophil dysplasia with cells that are charac-
teristic for Pelger-Huet anomaly. HSC/LSK, hematopoietic stem cells/Lin-;Scai+; Kit+; CMP, common 
myeloid progenitor; GMP, granulocyte-macrophage progenitor; MeP, megakaryocytic-erythroid 
progenitor; MDP, macrophage-dendritic cell progenitor; CD11B, pan marker for myeloid cells; 
Gr-1, marker for mature granulocytes.
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does not affect the viability of myeloid 
progenitors in mice may suggest that no 
negative selection due to reduced survival 
or proliferation by lack of miRNAs occurs 
in these cells. Together, these data provide 
evidence for a model in which reduced 
level of miRNAs is an oncogenic event 
in the development of leukemia but that 
activity of at least some miRNA species 
is essential for oncogenic transformation 
(Fig. 4). This is in full agreement with 
experimental data showing tumor sup-
pressing and oncogenic activities of inves-
tigated miRNAs, such as miR-17~92 and 
miR-125.43 Moreover, miRNA expression 
profiling data of human cancer and AML 
samples are consistent with this hypoth-
esis, as a small subset of miRNAs, includ-
ing e.g., miR-9, miR-125 and miR-17~92, 
are highly expressed, whereas most other 
miRNAs are downregulated.44
Dicer1 Mutations  
in Human Leukemia
To date, the mechanism behind the 
reduced miRNA expression in subsets of 
human myeloid leukemia samples still 
remains elusive. One possibility is that 
the widespread silencing of miRNAs is 
the result of a defect in miRNA biogenesis 
caused by mutations in the gene encoding 
DICER1. For instance, data from Cancer 
Genome Project at the Wellcome Trust 
Sanger Institute (www.sanger.ac.uk/cos-
mic) show that somatic DICER1 muta-
tions occur in different human tumors, 
including lung carcinoma, malignant 
melanoma and ovarian cancer.45 Recently, 
Hill et al. found DICER1 mutations in 
familial pleuro-pilmonary blastoma.46 In 
addition, a recent study in human non-epi-
thelial ovarian cancers revealed mutations 
in the codons encoding metal-binding 
sites within the RNase IIIb catalytic cen-
ters of DICER1 in 30 of 102 (29%) of 
the tumors.47 These authors also detected 
mutations in 1 out of 14 non-seminoma-
tous testicular germ-cell tumors, in 2 of 5 
embryonal rhabdomyosarcomas, and in 
1 of 266 epithelial ovarian and endome-
trial carcinomas.47 The RNase III domains 
of DICER1 are essential for miRNA mat-
uration, and introduced mutations in the 
RNase IIIa and in RNase IIIb abrogate in 
vitro processing of the 3p and 5p miRNAs, 
not affect lymphoma latency and overall 
survival.41 This discrepancy may indi-
cate that the tumorsuppressing activity of 
DICER1 is cell type-dependent.
We asked whether Dicer1 deletion 
enhances myeloid leukemia development 
in mice. In hematopoietic cells, C/ebpa 
starts to be expressed in early myeloid-
committed progenitors, making it a suit-
able promoter to drive Dicer1 deletion for 
studying the role of miRNA depletion in 
myeloid leukemias.34,42 To circumvent pre-
natal lethality, we transplanted fetal liver 
cells from mutant and control embryos 
into lethally irradiated recipient mice. 
While heterozygous deletion of Dicer1 in 
myeloid-committed progenitors does not 
affect myeloid development, homozygous 
Dicer1 deletion results in block of mac-
rophage/dendritic cell development and 
myeloid-dysplasia, a cellular condition that 
may be considered as a preleukemic state34 
(Fig. 2). However, mice transplanted with 
either heterozygous floxed Dicer1 or homo-
zygous floxed Dicer1 cells survived devoid 
of any signs of myelo-proliferative disease 
or leukemia development within a year of 
observation, indicating that loss of Dicer1 
in myeloid-committed progenitors is not 
sufficient to initiate short-term leukemo-
genesis in mice34 (Fig. 3A). To further 
investigate whether depletion of miRNAs 
accelerates myeloid leukemia development 
in a tumor susceptible model, we crossed 
Dicer1 floxed (Dicer1fl) alleles with p53fl/fl 
mice and transplanted fetal liver cells from 
double mutants and control embryos into 
lethally irradiated recipient mice. C/ebpa-
cre driven deletion of p53 and hemizygous 
deletion of Dicer1 in mice caused develop-
ment of various types of leukemias in half 
of the reconstituted mice with a latency 
of approximately 6 mo (Fig. 3). Only one 
out of eight Dicer1f/f;p53f/f recipient mice 
developed a leukemia with a latency of 
9 mo (Fig. 3A). However, PCR analysis on 
genomic DNA isolated from the Dicer1f/f 
tumor cells in liver and spleen showed that 
the Dicer1 floxed alleles were incompletely 
recombined (Fig. 3B). These results are 
in full agreement with data published by 
Kumar et al. and strongly suggest that only 
reduced levels of Dicer1, but not bialleleic 
loss of Dicer1, may play a functional role 
in leukemia development.39,40 However, 
the fact that total depletion of miRNAs 
monocytic and Dicer1-deficient cell line 
U937 suggests that some miRNAs can be 
generated by proteins other than DICER1, 
such as PIWIL4,35 but this hypothesis still 
needs proper validation. However, the fact 
that Dicer1-null monocytes are blocked 
in their differentiation in vivo indicates 
that Dicer1 is essential at this stage, and 
its function cannot be bypassed by other 
miRNA processing mechanisms.
MiRNA profiling of wild type GMPs 
showed that 104 miRNAs are abundantly 
expressed at this stage, of which at least 20 
miRNA families are potentially active by 
reducing their target mRNA abundance.34 
Interestingly, of the derepressed miRNA 
targets in Dicer1-null GMPs, 27% are nor-
mally exclusively expressed in HSCs or are 
specific for multi-potent progenitors and 
erythropoiesis.34 Unlike the results from 
HSCs and lymphoid progenitors show-
ing functions of Dicer1 mainly in survival 
pathways, these results provide evidence 
for a miRNA-controlled switch of a hema-
topoietic stem cell program of self-renewal 
and expansion toward myeloid differentia-
tion (Fig. 2).34
The Role for Dicer1 in Leukemia
Human cancer including different types 
of leukemia is characterized by a global 
reduction in miRNA expression.37 The 
first experimental evidence for a role of 
global downregulation of miRNAs in cel-
lular transformation and tumorigenesis has 
been presented in a K-Ras-induced mouse 
model for lung cancer.38 Further studies of 
the role for Dicer1 in human cancer devel-
opment in immune-deficient mice strongly 
suggested that Dicer1 is a haploinsufficient 
tumorsuppressor.39 In this model, homo-
zygous deletion of Dicer1 is tolerated by 
the tumor cells; however, lack of miR-
NAs abrogates tumor outgrowth due to 
strongly reduced cell proliferation capac-
ity of the DICER1-null cells.39 In agree-
ment, heterozygous deletion of Dicer1, but 
not Dicer1-knockout, accelerated tumor 
formation on a retinoblastoma-sensitized 
background.40 In mouse B-cells, Dicer1 is 
required for Myc-induced B-cell lympho-
magenesis and survival of B-cell lympho-
mas.41 However, in this model Dicer1 is 
not a haploinsufficient tumor suppressor, 
as heterozygous deletion of Dicer1 does 
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respectively.47,48 In agreement, transient 
expression experiments of mutant human 
DICER1 constructs in murine Dicer1-
null mesenchymal stem cells showed that 
inactivation of the RNase IIIb domain by 
mutation of D1709, results in complete 
loss of, particularly, 5p-derived mature 
miRNAs, including the tumor-suppres-
sive Let-7 family of miRNAs.49 This muta-
tion is found in subsets of nonepithelial 
ovarian cancers. Indeed, the identified 
Dicer1 hot spot mutations in cancer result 
in reduced RNase IIIb activity but retain 
RNase IIIa activity, strongly suggesting a 
positive selection for the mutations that 
reduces Let7-tumorsuppressing activity in 
cancer development.47
In a first attempt to gain more func-
tional insight into the mechanisms behind 
the reduced miRNA expression in AML, 
a panel of 45 AML samples, characterized 
by activation of the oncogene EVI-1 due 
to t(3;3)(q21;q26) or inv(3)(q21q26) and 
poor prognosis, and five AML cell lines, 
including U937, MOLM1, MUTZ3, 
KASUMI-3 and F36P, were sequenced. 
In this panel of high-risk AML samples, 
no mutation in Dicer1 coding sequences 
and untranslated regions were identified 
(unpublished data, Erkeland S.J., Valk P., 
Delwel H., Sanders M.A., Groschel S. and 
Hoogenboezem R., 2012). Despite the 
limited set of data, this result suggests that 
other mechanisms are involved in deregu-
lation of miRNA expression in human 
AML.
Different Mechanisms  
of DICER1 Activity Reduction  
in Human Leukemia
The expression of miRNAs may be 
deregulated by different mechanisms in 
human cancer.50 For instance, the activity 
of DICER1 may be reduced, as DICER1 
is frequently deleted in various human 
cancers.39 In addition, low expression of 
DICER1 independently predicted poor 
outcomes in ovarian cancer patients.51 In 
chronic lymphocytic leukemia (CLL), 
low expression of DICER1 has been cor-
related with increased aggressiveness of 
the disease, shorter overall survival as 
well as reduced treatment-free survival.52 
Notably, no such correlation between 
DICER1 transcript levels and disease 
Figure 3. Leukemia developed from C/ebpa-Cre; p53f/f; Dicer1f/wt HSCs. (A) Cumulative survival of 
mice transplanted with HSCs from fetal livers of C/ebpa-Cre; p53f/f; Dicer1 wt (n = 8), C/ebpa-Cre; 
p53f/f; Dicer1 f/wt (n = 12) and C/ebpa-Cre; p53f/f; Dicer1 f/f (n = 8) embryos. Significance: p < 0.05 
(log-rank Mantel-Cox test). (B) PCr on genomic DNA extracted from tumor cells. K.O., knockout 
allele; fl, floxed allele; wt, wild type allele; li, liver; BM, bone marrow; spl, spleen; con, control DNA 
heterozygous floxed Dicer1; neg, loading control. (C) example of tumor infiltration in liver and 
spleen of leukemic mice transplanted with C/ebpa-Cre; p5 f/f; Dicer f/wt HSCs. (D) Micrographs show-
ing morphology of tumor cells in blood, bone marrow and spleen. Bar indicates 10 μm.
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Mantel-Cox test was used to determine 
statistical significance.
Conclusion
Recent data show that Dicer1 is an essen-
tial factor at different stages of normal 
hematopoiesis. A limitation of the Dicer1-
deletion models is the global depletion of 
miRNAs that presumably results in dis-
ruption of many cellular pathways simulta-
neously, which hampers the identification 
of the functions of individual miRNAs. 
Although some studies show evidence for 
only a few miRNAs making dominant 
contributions, such as miR-17~92 in B-cell 
development, this may be different for 
other cell types or even be developmental 
stage-dependent. Overall, Dicer1 mainly 
controls survival and expansion at the 
early stages of lymphoid development and 
controls cellular activities at the terminal 
maturation stage. The function of Dicer1 
is different in myelopoiesis at the earliest 
developmental stage as Dicer1 is not essen-
tial for cell viability but instead controls 
essential steps in switching from the stem 
cell stage toward myeloid lineage devel-
opment. Although the functions of some 
miRNAs, such as miR-17/20/93/106 and 
miR-223, are well-described in immature 
and mature myeloid cells, respectively,56,63 
the miRNA-controlled pathways that 
are involved at different stages of myelo-
poiesis are still largely elusive. Therefore, 
embryonic day (E) 13.5. Genotyping of 
Dicer1; p53; C/ebpa-Cre;R26-LSL-Eyfp 
embryos was performed by PCR assays of 
DNA from tail or foot biopsies. Sequences 
of primers are available upon request. All 
primers were obtained from Biolegio BV. 
For transplantation, 8-week-old recipient 
mice C57Bl/6, (Jackson Laboratories) 
were irradiated (8.5 Gy) and tail-vein 
injected with fetal liver single-cell suspen-
sions. Typically, cells from each fetal liver 
were transplanted into two recipient mice. 
Tumorigenicity was subsequently moni-
tored by daily examination of the trans-
planted mice. Mice were euthanized when 
moribund. All animal experiments were 
approved by the Animal Welfare/Ethics 
Committee of the Erasmus Medical 
Center.
Antibodies, cell staining, flow cytom-
etry and cytospins. Peripheral blood was 
obtained by heart puncture at the moment 
of euthanasia. Bone marrow cell suspen-
sions were prepared as described previ-
ously.34 Tumor samples were prepared 
as single-cell suspension for cytospins or 
FACS analysis. For morphological analy-
sis of the cells, cytospins were stained with 
May-Grünwald-Giemsa and examined 
with a Leica DMLB microscope (100x 
and 40x objectives) and Leica Application 
Suite software version 2.7.1 R1.
Statistics. Kaplan-Meier survival 
curves were plotted using SPSS software 
(SPSS, PASW, 17.0.2), and log-rank 
outcome were found in human AML.53 
However, there is evidence for regulation 
of DICER1 expression by miRNAs such 
as miR-15a and miR-16 in a cohort of 
del(13q14) in CLL,52 miR-9 in Hodgkin 
lymphoma,54 miR-125 in human mega-
karyoblastic leukemia55 and miR-106a in 
the undifferentiated primary monocytes.35 
Interestingly, miR-9, miR-125 and miR-
106a are frequently aberrantly expressed 
at high levels in human AML44,56 (and 
review43) and may control DICER1 trans-
lation, leaving mRNA levels intact. Thus, 
aberrant miRNA biogenesis in human 
AML may occur via direct miRNA-con-
trolled feedback mechanisms on trans-
lation of DICER1 transcripts, but this 
hypothesis still needs proper experimental 
confirmation.
Reduction of miRNA expression may 
be controlled by other mechanisms as 
well. This hypothesis is supported by 
recently described mutations in the TAR 
RNA-binding protein 2 (TARBP2), a 
critical protein for processing miRNAs in 
sporadic and hereditary carcinomas, and 
the inactivating mutations in Exportin-5, 
which results in trap of pre-miRNAs in 
the nucleus in human cancer cells.57-59 
Other possible mechanisms behind aber-
rant miRNA expression are single nucleo-
tide polymorphisms (SNPs) that influence 
processing of miRNAs60 or RNA editing 
of miRNA precursors that blocks cleav-
age by DICER1.61,62 Sequencing of factors 
involved in the biogenesis of miRNAs or 
a better understanding of miRNA expres-
sion regulation by, e.g., transcription fac-
tors, epigenetic events or miRNA stability, 
are needed to unravel the mechanisms 
behind the reduced miRNA activity in 
human AML.
Methods
Mice and reconstitution experiments. 
To generate the different mouse lines 
of interest, we first crossed C/ebpa-
Cre;R26-LSL-Eyfp;Dicer1wt/fl mice34 with 
mice that contain floxed p53 conditional 
alleles (Jackson Laboratories). Finally, 
C/ebpa-Cre ;R26-LSL-Eyfp;Dicer1wt / f l /
Dicer1fl/ fl;p53 fl/fl mice were obtained from 
breeding C/ebpa-Cre;Dicer1wt/fl; p53fl/wt 
mice with R26-LSL-Eyfp;Dicer1fl/fl;p53 
fl/fl mice. Fetal livers were obtained on 
Figure 4. Model for the role of Dicer1 in leukemia development. Dicer1 knockout and as a result 
total loss of mirNA biogenesis, lead to myeloid dysplasia but not leukemia in a p53 knockout 
background. in contrast, heterozygous loss of Dicer1 conserves the expression of a set of mirNAs 
needed for normal differentiation. Furthermore, our model suggests that at least some mirNA 
activity is needed for oncogenic transformation.
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miRNA-add-back in the Dicer1-deficient 
models and experimental target identifi-
cation approaches may be of help for the 
understanding of the miRNA activities in 
hematopoiesis.
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